Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00800683 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 133
- Enrollment target
- 20
- Study locations
NCT00800683 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by Boehringer Ingelheim. The registered enrollment target is 133 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00800683, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 133 participants
- Enrollment target
- 20
- Study locations
Study Summary
to determine safety, efficacy and tolerability of BI 1356 versus placebo
Conditions Studied
Interventions
- DRUG placebo
- DRUG BI 1356
Study Locations (20)
California
- 1218.43.10011 Boehringer Ingelheim Investigational Site - Chula Vista
- 1218.43.10006 Boehringer Ingelheim Investigational Site - Riverside
- 1218.43.10021 Boehringer Ingelheim Investigational Site - Whittier
Florida
- 1218.43.10013 Boehringer Ingelheim Investigational Site - Pembroke Pines
- 1218.43.10009 Boehringer Ingelheim Investigational Site - West Palm Beach
New York
- 1218.43.10003 Boehringer Ingelheim Investigational Site - Great Neck
- 1218.43.10004 Boehringer Ingelheim Investigational Site - The Bronx
Ohio
- 1218.43.10019 Boehringer Ingelheim Investigational Site - Delaware
- 1218.43.10008 Boehringer Ingelheim Investigational Site - Mentor
Pennsylvania
- 1218.43.10005 Boehringer Ingelheim Investigational Site - Bethlehem
- 1218.43.10007 Boehringer Ingelheim Investigational Site - Carlisle
Arizona
- 1218.43.10027 Boehringer Ingelheim Investigational Site - Phoenix
Georgia
- 1218.43.10018 Boehringer Ingelheim Investigational Site - Decatur
Illinois
- 1218.43.10022 Boehringer Ingelheim Investigational Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00800683
The ClinicalTrials.gov registry entry for NCT00800683 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00800683 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00800683 about?
NCT00800683 is a clinical study titled "Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive". to determine safety, efficacy and tolerability of BI 1356 versus placebo
What is the current status of trial NCT00800683?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 133 participants. The study started on 2008-12.
What conditions does trial NCT00800683 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00800683?
The interventions under investigation include: placebo (DRUG), BI 1356 (DRUG).
Who is sponsoring clinical trial NCT00800683?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00800683 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.